Immatics N.V.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IMTX research report →
Range $15 – $21
Price Chart
About the company
Immatics N. V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United States.
- CEO
- Harpreet Singh
- IPO
- 2018
- Employees
- 704
- HQ
- Tübingen, BW, DE
Get TickerSpark's AI analysis on IMTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $863.40M
- P/E
- -3.24
- PEG
- 0.04
- P/S
- 18.63
- P/B
- 1.78
- EV/EBITDA
- -2.49
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -577.10%
- Net Margin
- -534.13%
- ROE
- -52.19%
- ROIC
- -53.62%
Latest fiscal year · YoY change
- Revenue
- $48.27M-69.0%
- Gross Profit
- $48.27M-69.0%
- Op Income
- $-182,016,000
- Net Income
- $-196,447,000-1390.9%
- EPS
- $-1.54-1200.0%
- OCF Growth
- -7.4%
- FCF Growth
- -0.8%
- 52W High
- $12.41
- 52W Low
- $5.71
- 50D MA
- $7.46
- 200D MA
- $9.36
- Beta
- 1.35
- RSI (14)
- 29
- Avg Volume
- 960.63K
No earnings-call transcripts are available for IMTX yet.
- Free Float
- 85.4%
- Shares Outstanding
- 149.64M
- Float Shares
- 127.72M
of shares held by institutions
86 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| T. Rowe Price Investment Management, Inc. | 25.15M | ▲ 2.78M |
| Rtw Investments, LP | 13.52M | ▲ 575.38K |
| Perceptive Advisors LLC | 11.25M | ▲ 863.06K |
| Vestal Point Capital, LP | 11.20M | ▲ 5.03M |
| Montanova Capital, LLC | 8.75M | ▼ 2.44M |
| Jefferies Financial Group Inc. | 6.42M | ▼ 84.02K |
| Wellington Management Group Llp | 4.32M | ▲ 2.67M |
| Baker Bros. Advisors LP | 4.26M | ▼ 5.25M |
| Sofinnova Investments, Inc. | 3.59M | ▼ 83.84K |
| Morgan Stanley | 2.31M | ▲ 126.41K |
| Orbimed Advisors LLC | 2.23M | ▲ 2.23M |
| Citadel Advisors LLC | 1.89M | ▲ 75.98K |
Held by 13 ETFs
Biggest fund positions in IMTX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 19, 26 | Kramer Rainer | other | 22,868 |
| Nov 19, 26 | Kramer Rainer | sell | 22,868 |
| Nov 19, 26 | Kramer Rainer | other | 22,868 |
| Aug 26, 26 | PERCEPTIVE ADVISORS LLC | buy | 863,060 |
| Aug 14, 26 | Pepin James Nelson | other | 181,200 |
| Aug 14, 26 | Pepin James Nelson | other | 43,800 |
| Jul 20, 26 | Pepin James Nelson | other | 0 |
| Jun 16, 26 | Stone Adam Leo | other | 48,000 |
| Jun 16, 26 | REICIN ALISE | other | 48,000 |
| Jun 16, 26 | ATIEH MICHAEL G | other | 48,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our IMTX coverage
Recent articles, reports, and earnings notes.
No research on IMTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IMTX report →Immatics (IMTX) Reports Q3 Loss, Lags Revenue Estimates
zacks.com · Nov 10
Immatics Announces Third Quarter 2026 Financial Results and Business Update
globenewswire.com · Nov 10
Immatics (IMTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
zacks.com · Nov 9
Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting
globenewswire.com · Oct 24
Immatics (NASDAQ:IMTX) vs. Kyntra Bio (NASDAQ:KYNB) Financial Contrast
defenseworld.net · Oct 9
Immatics (NASDAQ:IMTX) Reaches New 1-Year Low – Here’s Why
defenseworld.net · Oct 9
Immatics (NASDAQ:IMTX) Sees Strong Trading Volume – Still a Buy?
defenseworld.net · Oct 2
Immatics: 'Buy' On Anzu-Cel 1st Half 2027 Catalyst And Potential Label Expansion For Uveal Melanoma
seekingalpha.com · Aug 25
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.